T-Mobile US faces a pivotal moment as aggressive industry pricing and a tempered 2026 financial forecast clash with its robust operational performance and network leadership, prompting a major investor exit and forcing a reevaluation of its growth narrative.
First Hawaiian Bank reported a solid fourth quarter, driven by net interest margin expansion and loan growth, while outlining a cautious 2026 outlook. Executives highlighted Hawaii's resilient economy and strong credit quality, alongside a new, flexible $250 million share buyback program.
First Business Financial Services (FBIZ) reported robust 2025 results, driven by resilient margins and core deposit growth, while detailing a contained credit issue in its commercial real estate portfolio and outlining double-digit growth targets for the coming year.
A Goodyear, Arizona woman's attempt to fix her TV's closed captioning spiraled into a six-month ordeal, culminating in the loss of her life savings. This case highlights the sophisticated tactics of modern fraudsters and a dramatic surge in high-dollar scams targeting older adults.
A dual shift in U.S. sanctions and Venezuelan oil law is unlocking the country's vast reserves for American companies, marking a potential turning point after decades of nationalization and economic isolation.
After a November dip, Texas's upstream oil and gas sector added 2,000 jobs in December, contributing to the state's record-breaking employment figures and underscoring the industry's pivotal role in the Texan economy and tax base.
The Walt Disney Company announces plans for its first theme park in the Middle East—a full-scale resort in Abu Dhabi—alongside a key executive appointment aimed at refining long-term corporate strategy and investor relations.
Truist Securities adjusted its price target for American Healthcare REIT (NYSE: AHR) downward slightly, while affirming a Buy rating. The move comes as the firm reassesses its outlook for the broader REIT sector heading into 2026.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
In a dramatic market reversal, Bitcoin demonstrates resilience while gold and silver experience historic single-day declines, triggered by shifting interest rate expectations following a surprise Federal Reserve chair nomination.
A wave of subscription increases from Netflix, Disney, Apple, and others is forcing consumers to rethink their streaming budgets, with ad-supported tiers and strategic bundling emerging as key cost-saving strategies.
First Bank Corp. has entered into a definitive agreement to merge with Russellville-based First State Bank, a strategic move set to deepen the holding company's roots in the Arkansas River Valley region while preserving the community bank's local identity.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
While the small-cap index is a hunting ground for growth, some constituents face significant headwinds. We examine three companies where valuation and market dynamics warrant a cautious approach.
As the tech world's giants build their AI ambitions, chip designer Arm Holdings stands at the center. With its Q3 earnings report on the horizon, investors are weighing whether its foundational role justifies a premium valuation.
While low-volatility stocks offer a sense of security, they are not a guaranteed path to growth. We analyze one company with a stable profile and promising outlook, alongside two others where caution may be warranted despite their calm trading history.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
A Florida couple is suing their fertility clinic after discovering the baby girl born via IVF is not genetically related to them, sparking a complex legal and ethical battle over parentage and clinic accountability.
